| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:ONO-2952
CAS:895169-20-7
Package:1removed
|
Ethanone, 1-[(1'S)-1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',2',3',9'-tetrahydrospiro[cyclopropane-1,4'-[4H]pyrido[3,4-b]indol]-2'-yl]- manufacturers
- ONO-2952
-
- $2800.00
-
2026-05-11
- CAS:895169-20-7
- Purity:
- Supply Ability: 10g
|
| | Ethanone, 1-[(1'S)-1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',2',3',9'-tetrahydrospiro[cyclopropane-1,4'-[4H]pyrido[3,4-b]indol]-2'-yl]- Basic information |
| Product Name: | Ethanone, 1-[(1'S)-1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',2',3',9'-tetrahydrospiro[cyclopropane-1,4'-[4H]pyrido[3,4-b]indol]-2'-yl]- | | Synonyms: | Ethanone, 1-[(1'S)-1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',2',3',9'-tetrahydrospiro[cyclopropane-1,4'-[4H]pyrido[3,4-b]indol]-2'-yl]-;ONO2952,ONO 2952;ONO-2952 | | CAS: | 895169-20-7 | | MF: | C22H20ClFN2O2 | | MW: | 398.86 | | EINECS: | | | Product Categories: | | | Mol File: | 895169-20-7.mol | ![Ethanone, 1-[(1'S)-1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',2',3',9'-tetrahydrospiro[cyclopropane-1,4'-[4H]pyrido[3,4-b]indol]-2'-yl]- Structure](CAS/20200401/GIF/895169-20-7.gif) |
| | Ethanone, 1-[(1'S)-1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',2',3',9'-tetrahydrospiro[cyclopropane-1,4'-[4H]pyrido[3,4-b]indol]-2'-yl]- Chemical Properties |
| form | Solid | | color | White to off-white |
| | Ethanone, 1-[(1'S)-1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',2',3',9'-tetrahydrospiro[cyclopropane-1,4'-[4H]pyrido[3,4-b]indol]-2'-yl]- Usage And Synthesis |
| Uses | ONO-2952 is a potent, selective and orally active translocator protein 18 kDa (TSPO) antagonist with Ki of 0.33-9.30 nM for rat and human TSPO. ONO-2952 is more selective for TSPO than other receptors, transporters, ion channels and enzymes. ONO-2952 exerts its anti-stress effects through inhibition of excessive activation of noradrenergic system in the brain without the amnesic effect. ONO-2952 has the potential for irritable bowel syndrome treatment[1][2]. | | in vivo | ONO-2952 (0.03-3 mg/kg; oral administration; male Sprague Dawley rats) treatment dose-dependently suppresses restraint stress-induced defecation in rats with brain TSPO occupancy of more than 50%. ONO-2952 also suppresses conditioned fear stress-induced freezing behavior in rats[1].
ONO-2952 inhibits both neurosteroid accumulation and noradrenaline release in the brain of rats exposed to acute stress[1]. | Animal Model: | Male Sprague Dawley rats (8 weeks old) under conditioned fear stress test[1] | | Dosage: | 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg | | Administration: | Oral administration | | Result: | Dose-dependently suppressed restraint stress-induced defecation in rats. And suppressed conditioned fear stress-induced freezing behavior in rats.
|
| | References | [1] Mitsui K, et al. Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015 Dec;99:51-66. DOI:10.1016/j.neuropharm.2015.07.011
[2] Whitehead WE, et al. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2017 Jan;45(1):14-26. DOI:10.1111/apt.13839 |
| | Ethanone, 1-[(1'S)-1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',2',3',9'-tetrahydrospiro[cyclopropane-1,4'-[4H]pyrido[3,4-b]indol]-2'-yl]- Preparation Products And Raw materials |
|